Skip to content
OpenCapital
Get started

Candel Therapeutics, Inc. CADL Q1 2026 earnings

Reported May 14, 2026 · Before market open

EPS-$0.14Beat by $0.08
EPS estimate-$0.22

Next report

Aug 13, 2026 (In 2 weeks)
EPS estimate-$0.22

Financials

Q1 2026

Income statement

See full
Operating income-$16.3M-100%
Net income-$8.9M-220%
EPS (diluted)-$0.14-208%

Balance sheet

See full
Cash & equivalents$194.8M+111%
Total debt$2.8M-73.9%
Total equity$138.0M+84.8%
Total assets$201.9M+111%

Cash flow

See full
Operating cash flow-$18.0M-109%
CapEx$675.0K+22,400%
Free cash flow-$18.7M-117%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$729.77M+112%
Enterprise value$537.78M+114%

Returns & leverage

See full
Return on equity-51.2%-16.6pp
Debt / equity0×-0.1×
Current ratio28×+23.4×

Versus estimates

Diluted EPS

Q1 2026-$0.14Beat by $0.08
Q4 2025-$0.54Miss by $0.30Q3 2025-$0.21Miss by $0.04Q2 2025-$0.09Beat by $0.08Q1 2025$0.13Beat by $0.37Q4 2024-$0.40Miss by $0.17

Ask the moment Candel Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Candel Therapeutics, Inc. report Q1 2026 earnings?
Candel Therapeutics, Inc. (CADL) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Candel Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Candel Therapeutics, Inc. reported eps of $-0.14 for Q1 2026.
Did Candel Therapeutics, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.22 by $0.08.
Where can I find Candel Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-222892) and the 10-Q periodic report (0001193125-26-222904) directly on SEC EDGAR. The filing index links above go to sec.gov.